Addison Advisors LLC Increases Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Addison Advisors LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 52.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 311 shares of the medical equipment provider’s stock after buying an additional 107 shares during the quarter. Addison Advisors LLC’s holdings in Intuitive Surgical were worth $105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Intuitive Surgical by 0.7% in the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after buying an additional 196,316 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Intuitive Surgical by 6.4% during the third quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock valued at $1,340,205,000 after acquiring an additional 274,692 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Intuitive Surgical by 6.6% during the third quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock valued at $1,096,231,000 after acquiring an additional 232,205 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Intuitive Surgical by 3.4% in the third quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider’s stock valued at $1,027,230,000 after purchasing an additional 115,059 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Intuitive Surgical by 0.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,030,415 shares of the medical equipment provider’s stock valued at $593,470,000 after purchasing an additional 17,477 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Mark Brosius sold 196 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares in the company, valued at $736,800. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Mark Brosius sold 196 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares in the company, valued at $736,800. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 249,418 shares of company stock worth $96,300,959. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG traded up $2.21 during midday trading on Friday, hitting $375.33. 927,845 shares of the stock were exchanged, compared to its average volume of 1,564,565. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The stock has a fifty day simple moving average of $386.19 and a 200 day simple moving average of $346.29. The firm has a market cap of $133.13 billion, a P/E ratio of 67.75, a P/E/G ratio of 4.85 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same period last year, the business posted $1.00 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ISRG has been the subject of several recent research reports. Raymond James increased their price target on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Royal Bank of Canada increased their price target on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Citigroup increased their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. StockNews.com lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Finally, Jefferies Financial Group increased their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.